Schroder Investment Management Group Cuts Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Schroder Investment Management Group reduced its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 5.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,125,618 shares of the company's stock after selling 61,166 shares during the period. Schroder Investment Management Group owned about 0.52% of Hims & Hers Health worth $28,332,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. Crewe Advisors LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Raleigh Capital Management Inc. increased its holdings in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 1,100 shares in the last quarter. Blume Capital Management Inc. increased its holdings in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 600 shares in the last quarter. Smartleaf Asset Management LLC raised its position in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after acquiring an additional 1,413 shares during the period. Finally, US Bancorp DE lifted its holdings in Hims & Hers Health by 346.7% during the fourth quarter. US Bancorp DE now owns 1,943 shares of the company's stock valued at $47,000 after purchasing an additional 1,508 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 4,152 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now owns 157,345 shares of the company's stock, valued at $9,549,268.05. The trade was a 2.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Oluyemi Okupe sold 11,581 shares of the firm's stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $29.26, for a total value of $338,860.06. Following the transaction, the chief financial officer now owns 124,104 shares of the company's stock, valued at approximately $3,631,283.04. This represents a 8.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 809,806 shares of company stock worth $30,923,658 over the last quarter. 17.71% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on HIMS. Bank of America boosted their target price on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an "underperform" rating in a research note on Tuesday, March 18th. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Needham & Company LLC raised their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research report on Tuesday, February 25th. Leerink Partners increased their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. Finally, Truist Financial raised their price objective on Hims & Hers Health from $24.00 to $39.00 and gave the company a "hold" rating in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health currently has a consensus rating of "Hold" and an average target price of $37.31.

Hims & Hers Health Trading Up 6.6 %

Hims & Hers Health stock traded up $1.72 during midday trading on Monday, hitting $27.71. 26,460,112 shares of the stock were exchanged, compared to its average volume of 14,777,841. The stock's 50-day simple moving average is $39.76 and its 200 day simple moving average is $30.11. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98. The stock has a market capitalization of $6.16 billion, a price-to-earnings ratio of 62.97 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.